Loading...
Market
How many new clinical trials for Eftilagimod Alpha will be initiated in 2024?
2
Resolution / Starting Odds
0 • 25%
1 - 2 • 25%
3 - 4 • 25%
5 or more • 25%
Clinical trial registries such as ClinicalTrials.gov and official announcements by Immutep
Story
Immutep Reports Positive Results in PD-L1-Negative Head and Neck Cancer with Eftilagimod Alpha and Pembrolizumab
Jul 12, 2024, 01:54 PM
Immutep has reported positive results in first-line treatment of head and neck squamous cell carcinoma (HNSCC) patients with negative PD-L1 expression. The results were achieved using a combination of Eftilagimod Alpha and Pembrolizumab, which generated a favorable overall response rate (ORR). This announcement has led to an 18.4% pre-market increase in Immutep's stock price ($IMMP). The findings were highlighted during the ESMO Virtual Plenary and have been met with significant interest in the oncology community. The results were reported by SI.
View original story
Similar markets
0-5 trials • 25%
6-10 trials • 25%
11-15 trials • 25%
More than 15 trials • 25%
0-2 trials • 25%
3-5 trials • 25%
6-8 trials • 25%
More than 8 trials • 25%
Yes • 50%
No • 50%
Phase 1 • 25%
Phase 2 • 25%
Phase 3 • 25%
Phase 4 • 25%
Completed with positive results • 25%
Completed with negative results • 25%
Not completed • 25%
Unknown/Other • 25%
1-2 countries • 25%
3-4 countries • 25%
5-6 countries • 25%
7 or more countries • 25%
0-5 trials • 25%
6-10 trials • 25%
11-15 trials • 25%
More than 15 trials • 25%
Yes • 50%
No • 50%
Dose escalation • 25%
Safety assessment • 25%
Efficacy assessment • 25%
Trial termination • 25%
0-5 trials • 25%
6-10 trials • 25%
11-15 trials • 25%
More than 15 trials • 25%
0 • 25%
1-3 • 25%
4-6 • 25%
More than 6 • 25%